It has extensively been reported that these anti-tumour drugs impact the tumour microenvironment (TME), target human tumour-associated macrophages (hTAM) [46,71,72,73], and inhibit the transcription of pro-inflammatory cytokines such as CCL2 (chemokine ligand 2), IL-6 [74], VEGF [65], CCL3, CCL7, and CCL14 [53,75]. This evidence concerns the gene IL6 and neoplasm.